Provention Bio Inc. (PRVB) Announces Proposed 5.5M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Provention Bio Inc. (PRVB) Prices 6.6M Share Common Offering at $14.50/Sh
June 18, 2020 5:58 AM UTCProvention Bio, Inc., (NASDAQ: PRVB) today announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share. Gross proceeds to Provention Bio from the offering are expected to be $95.7 million, before deducting underwriting discounts... More
Provention Bio Inc. (PRVB) PT Raised to $26 at H.C. Wainwright
June 16, 2020 6:34 AM UTCH.C. Wainwright analyst Raghuram Selvaraju raised the price target on Provention Bio Inc. (NASDAQ: PRVB) to $26.00 (from $20.00) while maintaining a Buy rating.... More
Provention Bio Inc. (PRVB) Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients
June 15, 2020 12:09 PM UTCProvention Bio, Inc. (Nasdaq: PRVB) announced extended follow-up data showing a single 14-day course of teplizumab (PRV-031) significantly delayed the onset of insulin-dependent type 1 diabetes (T1D) in presymptomatic patients by a median of approximately three years compared to placebo. These new data from the pivotal "At-Risk" TN-10 Study add one year to the two-year median delay that was previously reported in the New England Journal of Medicine and presented at last year's American Diabetes Association's (ADA's) Scientific Sessions. Teplizumab, Provention's lead drug candidate, is an anti-CD3 monoclonal antibody in development for the... More
Provention Bio Inc. (PRVB) gains on talk of positive diabetes data
June 15, 2020 11:31 AM UTCProvention Bio Inc. (NASDAQ: PRVB) gains on talk of positive diabetes data.
... More